Search Results
U1149 – University Paris Diderot, Paris, France
Search for other papers by J Cros in
Google Scholar
PubMed
Search for other papers by O Hentic in
Google Scholar
PubMed
Department of Gastroenterology and Pancreatology, AP-HP, DHU UNITY, Beaujon University Hospital, Clichy, France
Search for other papers by V Rebours in
Google Scholar
PubMed
Search for other papers by M Zappa in
Google Scholar
PubMed
Search for other papers by N Gille in
Google Scholar
PubMed
Search for other papers by N Theou-Anton in
Google Scholar
PubMed
Search for other papers by D Vernerey in
Google Scholar
PubMed
Search for other papers by F Maire in
Google Scholar
PubMed
Department of Gastroenterology and Pancreatology, AP-HP, DHU UNITY, Beaujon University Hospital, Clichy, France
Search for other papers by P Lévy in
Google Scholar
PubMed
U1149 – University Paris Diderot, Paris, France
Search for other papers by P Bedossa in
Google Scholar
PubMed
U1149 – University Paris Diderot, Paris, France
Search for other papers by V Paradis in
Google Scholar
PubMed
Department of Digestive Oncology, AP-HP, DHU UNITY, Beaujon University Hospital, Clichy, France
Search for other papers by P Hammel in
Google Scholar
PubMed
Department of Gastroenterology and Pancreatology, AP-HP, DHU UNITY, Beaujon University Hospital, Clichy, France
Search for other papers by P Ruszniewski in
Google Scholar
PubMed
Department of Pathology, AP-HP, DHU UNITY, Bichat University Hospital, Paris, France
Search for other papers by A Couvelard in
Google Scholar
PubMed
Introduction Evidences suggesting the efficacy of temozolomide (TEM), a DNA-alkylating agent, in advanced pancreatic neuroendocrine tumors (PNETs) are accumulating ( Kulke et al. 2006 , Ekeblad et al. 2007 , Strosberg et al. 2011
Search for other papers by Simona Falletta in
Google Scholar
PubMed
Search for other papers by Stefano Partelli in
Google Scholar
PubMed
Search for other papers by Corrado Rubini in
Google Scholar
PubMed
Search for other papers by Dominik Nann in
Google Scholar
PubMed
Search for other papers by Andrea Doria in
Google Scholar
PubMed
Search for other papers by Ilaria Marinoni in
Google Scholar
PubMed
Search for other papers by Vanessa Polenta in
Google Scholar
PubMed
Search for other papers by Carmelina Di Pasquale in
Google Scholar
PubMed
Search for other papers by Ettore degli Uberti in
Google Scholar
PubMed
Search for other papers by Aurel Perren in
Google Scholar
PubMed
Search for other papers by Massimo Falconi in
Google Scholar
PubMed
Search for other papers by Maria Chiara Zatelli in
Google Scholar
PubMed
Introduction Pancreatic neuroendocrine tumors (P-NETs) are heterogeneous neoplasms originating from pancreatic neuroendocrine cells ( Singh et al. 2015 , Berardi et al . 2016 ), representing 1–4% of all pancreatic malignancies, with an
Search for other papers by Brendan M Finnerty in
Google Scholar
PubMed
Search for other papers by Maureen D Moore in
Google Scholar
PubMed
Search for other papers by Akanksha Verma in
Google Scholar
PubMed
Search for other papers by Anna Aronova in
Google Scholar
PubMed
Search for other papers by Shixia Huang in
Google Scholar
PubMed
Search for other papers by Dean P Edwards in
Google Scholar
PubMed
Search for other papers by Zhengming Chen in
Google Scholar
PubMed
Search for other papers by Marco Seandel in
Google Scholar
PubMed
Search for other papers by Theresa Scognamiglio in
Google Scholar
PubMed
Search for other papers by Yi-Chieh Nancy Du in
Google Scholar
PubMed
Search for other papers by Olivier Elemento in
Google Scholar
PubMed
Search for other papers by Rasa Zarnegar in
Google Scholar
PubMed
Search for other papers by Irene M Min in
Google Scholar
PubMed
Search for other papers by Thomas J Fahey III in
Google Scholar
PubMed
Introduction Pancreatic neuroendocrine tumors (PNETs) are rare tumors comprising only 2% of all pancreatic tumors, with a twofold increase in incidence since 1975 ( Halfdanarson et al. 2008 , Lawrence et al. 2011 ). The role of genetic
Search for other papers by Mojun Zhu in
Google Scholar
PubMed
Search for other papers by Karl R Sorenson in
Google Scholar
PubMed
Search for other papers by Rebecca Liu in
Google Scholar
PubMed
Search for other papers by Bonnie E Gould Rothberg in
Google Scholar
PubMed
Search for other papers by Thorvardur R Halfdanarson in
Google Scholar
PubMed
Introduction Pancreatic neuroendocrine tumors (PNETs) are a group of heterogeneous malignancies with diverse pathological findings and clinical behaviors. With an annual incidence that is less than 1 per 100,000 ( Halfdanarson et al. 2008
Université de Paris, Centre de Recherche sur l’Inflammation, INSERM, Paris, France
Search for other papers by Ophélie De Rycke in
Google Scholar
PubMed
Search for other papers by Thomas Walter in
Google Scholar
PubMed
Search for other papers by Marine Perrier in
Google Scholar
PubMed
Search for other papers by Olivia Hentic in
Google Scholar
PubMed
Search for other papers by Catherine Lombard-Bohas in
Google Scholar
PubMed
Search for other papers by Romain Coriat in
Google Scholar
PubMed
Search for other papers by Guillaume Cadiot in
Google Scholar
PubMed
Department of Pathology, ENETS Centre of Excellence, Bichat/Beaujon University Hospital, Paris/Clichy, France
Search for other papers by Anne Couvelard in
Google Scholar
PubMed
Université de Paris, Centre de Recherche sur l’Inflammation, INSERM, Paris, France
Search for other papers by Philippe Ruszniewski in
Google Scholar
PubMed
Department of Pathology, ENETS Centre of Excellence, Bichat/Beaujon University Hospital, Paris/Clichy, France
Search for other papers by Jérôme Cros in
Google Scholar
PubMed
Université de Paris, Centre de Recherche sur l’Inflammation, INSERM, Paris, France
Search for other papers by Louis de Mestier in
Google Scholar
PubMed
Introduction Pancreatic neuroendocrine tumors (PanNET) are a heterogeneous group of rare neoplasms. However, in the past few decades, their incidence has increased for all grades and stages ( Dasari et al. 2017 ). Approximately 20% of PanNET
Search for other papers by Sonia M Abuzakhm in
Google Scholar
PubMed
Search for other papers by Vineeth Sukrithan in
Google Scholar
PubMed
Search for other papers by Briant Fruth in
Google Scholar
PubMed
Search for other papers by Rui Qin in
Google Scholar
PubMed
Search for other papers by Jonathan Strosberg in
Google Scholar
PubMed
Search for other papers by Timothy J Hobday in
Google Scholar
PubMed
Search for other papers by Thomas Semrad in
Google Scholar
PubMed
Search for other papers by Diane Reidy-Lagunes in
Google Scholar
PubMed
Search for other papers by Hedy Lee Kindler in
Google Scholar
PubMed
Search for other papers by George P Kim in
Google Scholar
PubMed
Search for other papers by Jennifer J Knox in
Google Scholar
PubMed
Search for other papers by Andreas Kaubisch in
Google Scholar
PubMed
Search for other papers by Miguel Villalona-Calero in
Google Scholar
PubMed
Search for other papers by Helen Chen in
Google Scholar
PubMed
Search for other papers by Charles Erlichman in
Google Scholar
PubMed
Search for other papers by Manisha H Shah in
Google Scholar
PubMed
patients with advanced extra-pancreatic neuroendocrine tumors. Around 54% of patients discontinued treatment due to adverse events, refusal of further treatment, or treatment delays. Given the increased toxicity observed with the combination, particularly
Search for other papers by Olga Lakiza in
Google Scholar
PubMed
Search for other papers by Julian Lutze in
Google Scholar
PubMed
Search for other papers by Alyx Vogle in
Google Scholar
PubMed
Search for other papers by Jelani Williams in
Google Scholar
PubMed
Search for other papers by Abde Abukdheir in
Google Scholar
PubMed
Search for other papers by Paul Miller in
Google Scholar
PubMed
Search for other papers by Chih-Yi ‘Andy’ Liao in
Google Scholar
PubMed
Search for other papers by Sean P Pitroda in
Google Scholar
PubMed
Search for other papers by Carlos Martinez in
Google Scholar
PubMed
Search for other papers by Andrea Olivas in
Google Scholar
PubMed
Search for other papers by Namrata Setia in
Google Scholar
PubMed
Department of Molecular Genetics and Cell Biology, University of Chicago, Chicago, Illinois, USA
Search for other papers by Stephen J Kron in
Google Scholar
PubMed
Ludwig Center for Metastasis Research, University of Chicago, Chicago, Illinois, USA
Search for other papers by Ralph R Weichselbaum in
Google Scholar
PubMed
Search for other papers by Xavier M Keutgen in
Google Scholar
PubMed
Introduction Pancreatic neuroendocrine tumors (PanNET) are rare, but their incidence is steadily increasing. Patients with PanNETs present with metastatic disease in 50–70% of cases and less than 50% will survive longer than 5 years
Search for other papers by M Cives in
Google Scholar
PubMed
Search for other papers by M Ghayouri in
Google Scholar
PubMed
Search for other papers by B Morse in
Google Scholar
PubMed
Search for other papers by M Brelsford in
Google Scholar
PubMed
Search for other papers by M Black in
Google Scholar
PubMed
Search for other papers by A Rizzo in
Google Scholar
PubMed
Search for other papers by A Meeker in
Google Scholar
PubMed
Search for other papers by J Strosberg in
Google Scholar
PubMed
Introduction Chemotherapy regimens containing the oral alkylating agent temozolomide are active in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs), with response rates ranging from 30 to 70% ( Kulke et al . 2006
Search for other papers by Margaux Foulfoin in
Google Scholar
PubMed
University of Lyon, Université Lyon 1, Lyon, France
Search for other papers by Emmanuelle Graillot in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de chirurgie, Lyon, France
Search for other papers by Mustapha Adham in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de radiologie, Lyon, France
Search for other papers by Pascal Rousset in
Google Scholar
PubMed
Search for other papers by Julien Forestier in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Edouard Herriot, Service Central d’Anatomie et Cytologie Pathologiques, Lyon, France
Search for other papers by Valérie Hervieu in
Google Scholar
PubMed
Search for other papers by Philip Robinson in
Google Scholar
PubMed
Search for other papers by Jean-Yves Scoazec in
Google Scholar
PubMed
Search for other papers by Catherine Lombard-Bohas in
Google Scholar
PubMed
University of Lyon, Université Lyon 1, Lyon, France
Search for other papers by Thomas Walter in
Google Scholar
PubMed
Introduction The prevalence of pancreatic neuroendocrine tumors (P-NET) is 0.32 per 100,000 in the US, and the incidence is rising ( Yao et al . 2008 ). The median survival is longer than that in pancreatic adenocarcinoma, and patients
Search for other papers by Tobias Krauss in
Google Scholar
PubMed
Search for other papers by Alfonso Massimiliano Ferrara in
Google Scholar
PubMed
Search for other papers by Thera P Links in
Google Scholar
PubMed
Search for other papers by Ulrich Wellner in
Google Scholar
PubMed
Search for other papers by Irina Bancos in
Google Scholar
PubMed
Search for other papers by Andrey Kvachenyuk in
Google Scholar
PubMed
Search for other papers by Karina Villar Gómez de las Heras in
Google Scholar
PubMed
Search for other papers by Marina Y Yukina in
Google Scholar
PubMed
Search for other papers by Roman Petrov in
Google Scholar
PubMed
Search for other papers by Garrett Bullivant in
Google Scholar
PubMed
Search for other papers by Laura von Duecker in
Google Scholar
PubMed
Search for other papers by Swati Jadhav in
Google Scholar
PubMed
Search for other papers by Ursula Ploeckinger in
Google Scholar
PubMed
Search for other papers by Staffan Welin in
Google Scholar
PubMed
Search for other papers by Camilla Schalin-Jäntti in
Google Scholar
PubMed
Search for other papers by Oliver Gimm in
Google Scholar
PubMed
Search for other papers by Marija Pfeifer in
Google Scholar
PubMed
Search for other papers by Joanne Ngeow in
Google Scholar
PubMed
Search for other papers by Kornelia Hasse-Lazar in
Google Scholar
PubMed
Search for other papers by Gabriela Sansó in
Google Scholar
PubMed
Search for other papers by Xiaoping Qi in
Google Scholar
PubMed
Search for other papers by M Umit Ugurlu in
Google Scholar
PubMed
Search for other papers by Rene E Diaz in
Google Scholar
PubMed
Search for other papers by Nelson Wohllk in
Google Scholar
PubMed
Search for other papers by Mariola Peczkowska in
Google Scholar
PubMed
Search for other papers by Jens Aberle in
Google Scholar
PubMed
Search for other papers by Delmar M Lourenço Jr in
Google Scholar
PubMed
Search for other papers by Maria A A Pereira in
Google Scholar
PubMed
Search for other papers by Maria C B V Fragoso in
Google Scholar
PubMed
Search for other papers by Ana O Hoff in
Google Scholar
PubMed
Search for other papers by Madson Q Almeida in
Google Scholar
PubMed
Search for other papers by Alice H D Violante in
Google Scholar
PubMed
Search for other papers by Ana R P Quidute in
Google Scholar
PubMed
Search for other papers by Zhewei Zhang in
Google Scholar
PubMed
Search for other papers by Mònica Recasens in
Google Scholar
PubMed
Search for other papers by Luis Robles Díaz in
Google Scholar
PubMed
Search for other papers by Tada Kunavisarut in
Google Scholar
PubMed
Search for other papers by Taweesak Wannachalee in
Google Scholar
PubMed
Search for other papers by Sirinart Sirinvaravong in
Google Scholar
PubMed
Search for other papers by Eric Jonasch in
Google Scholar
PubMed
Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed
Search for other papers by Merav Fraenkel in
Google Scholar
PubMed
Search for other papers by Dmitry Beltsevich in
Google Scholar
PubMed
Search for other papers by Viacheslav I Egorov in
Google Scholar
PubMed
Search for other papers by Dirk Bausch in
Google Scholar
PubMed
Search for other papers by Matthias Schott in
Google Scholar
PubMed
Search for other papers by Nikolaus Tiling in
Google Scholar
PubMed
Search for other papers by Gianmaria Pennelli in
Google Scholar
PubMed
Search for other papers by Stefan Zschiedrich in
Google Scholar
PubMed
Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany
Search for other papers by Roland Därr in
Google Scholar
PubMed
Search for other papers by Juri Ruf in
Google Scholar
PubMed
Search for other papers by Timm Denecke in
Google Scholar
PubMed
Search for other papers by Karl-Heinrich Link in
Google Scholar
PubMed
Search for other papers by Stefania Zovato in
Google Scholar
PubMed
Search for other papers by Ernst von Dobschuetz in
Google Scholar
PubMed
Search for other papers by Svetlana Yaremchuk in
Google Scholar
PubMed
Search for other papers by Holger Amthauer in
Google Scholar
PubMed
Search for other papers by Özer Makay in
Google Scholar
PubMed
Search for other papers by Attila Patocs in
Google Scholar
PubMed
Search for other papers by Martin K Walz in
Google Scholar
PubMed
Search for other papers by Tobias B Huber in
Google Scholar
PubMed
Search for other papers by Jochen Seufert in
Google Scholar
PubMed
Search for other papers by Per Hellman in
Google Scholar
PubMed
Search for other papers by Raymond H Kim in
Google Scholar
PubMed
Search for other papers by Ekaterina Kuchinskaya in
Google Scholar
PubMed
Search for other papers by Francesca Schiavi in
Google Scholar
PubMed
Search for other papers by Angelica Malinoc in
Google Scholar
PubMed
Search for other papers by Nicole Reisch in
Google Scholar
PubMed
Search for other papers by Barbara Jarzab in
Google Scholar
PubMed
Search for other papers by Marta Barontini in
Google Scholar
PubMed
Search for other papers by Andrzej Januszewicz in
Google Scholar
PubMed
Search for other papers by Nalini Shah in
Google Scholar
PubMed
Search for other papers by William F Young Jr in
Google Scholar
PubMed
Search for other papers by Giuseppe Opocher in
Google Scholar
PubMed
Search for other papers by Charis Eng in
Google Scholar
PubMed
Search for other papers by Hartmut P H Neumann in
Google Scholar
PubMed
Search for other papers by Birke Bausch in
Google Scholar
PubMed
). Pancreatic neuroendocrine tumors (PanNETs) originate from the islets of the pancreas and may be hormonally active or inactive. PanNETs occur mainly as sporadic tumors, but 9% are also components of three hereditary syndromes, multiple endocrine neoplasia type